The latest news from academia, regulators
research labs and other things of interest
Posted: January 22, 2008
Arrowhead CEO Invited to Give Keynote Presentation at Rice Alliance Nanotechnology Venture Forum
(Nanowerk News) Arrowhead Research Corporation (Nasdaq:ARWR), announced today that its President & CEO, Dr. Christopher Anzalone, will present at the 7th Annual Rice Alliance Nanotechnology Forum on January 24, 2008 at 4:00 pm CT in Houston, Texas. Dr. Anzalone will highlight how Arrowhead’s unique business model leverages university nanotechnology into capital efficient nanotech companies making products for electronics, energy and life sciences.
The Rice Alliance for Technology and Entrepreneurship supports entrepreneurs and early-stage technology ventures in Houston and Texas through education, collaboration, and research. Since inception in late 1999, the Rice Alliance has assisted in the launch of over 205 technology companies that have raised more than $300 million in funding. The Annual Nanotechnology Forum is one of the largest venture forums in North America and showcases the 20 most promising companies in nanotechnology.
About Arrowhead Research Corporation
Arrowhead Research Corporation (www.arrowheadresearch.com) (NASDAQ:ARWR) is a leading nanotechnology company commercializing new technologies in the areas of life sciences, electronics and energy. Arrowhead is building value for shareholders through the progress of majority owned subsidiaries founded on nanotechnologies originally developed at universities. The company works closely with universities to source early stage deals and to generate rights to intellectual property covering promising new nanotechnologies. Currently, Arrowhead has five subsidiaries commercializing nanotech products and applications, including anti-cancer drugs, RNAi therapeutics, fullerene anti-oxidants, carbon-based electronics and compound semiconductor materials.
Safe Harbor Statement under the Private Securities Litigation Reform Act of 1995:
This news release contains forward-looking statements within the meaning of the "safe harbor" provisions of the Private Securities Litigation Reform Act of 1995. These statements are based upon our current expectations and speak only as of the date hereof. Our actual results may differ materially and adversely from those expressed in any forward-looking statements as a result of various factors and uncertainties, including the future success of our clinical studies, our ability to successfully develop and manufacture products, rapid technological change in our industry, changes in demand for our future products, legislative, regulatory and competitive developments and general economic conditions. Our Annual Report on Form 10-K, and other SEC filings discuss these and other important risk factors that may affect our business, results of operations and financial condition. We undertake no obligation to revise or update publicly any forward-looking statements for any reason.